-
Something wrong with this record ?
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
AM. Spanjaart, P. Ljungman, G. Tridello, J. Schwartz, N. Martinez-Cibrián, P. Barba, M. Kwon, L. Lopez-Corral, J. Martinez-Lopez, C. Ferra, R. Di Blasi, H. Ghesquieres, P. Mutsaers, F. Calkoen, M. Jak, J. van Doesum, JSP. Vermaat, M. van der...
Language English Country England, Great Britain
Document type Journal Article, Multicenter Study
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Receptors, Chimeric Antigen immunology MeSH
- COVID-19 * therapy immunology mortality MeSH
- Child MeSH
- Adult MeSH
- Hematologic Neoplasms * therapy mortality immunology MeSH
- Immunotherapy, Adoptive * methods adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Young Adult MeSH
- Child, Preschool MeSH
- SARS-CoV-2 * immunology MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Europe MeSH
COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
Adult HSCT unit Northern Centre for Bone Marrow Transplantation Newcastle Tyne UK
Blood and Bone Marrow Transplantation Department University Hospital of Cardiff Cardiff UK
Cell Therapy and Transfusion Medicine Unit Azienda Ospedaliero Universitaria Careggi Firenze Italy
Cellular Therapy and immunobiology working party of EBMT
Chaim Sheba Medical Center Tel Aviv University Tel Hashomer Israel
Department of Haematology The Royal Marsden Hospital London United Kingdom
Department of Haematology University College London Hospital London UK
Department of Haematology University Hospitals Bristol and Weston NHSFT Bristol UK
Department of Hematology and Cellular Therapy IRCCS Ospedale Policlinico San Martino Genova Italy
Department of Hematology Assistance Publique Hôpitaux de Paris Hopital Saint Louis Paris France
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology Erasmus MC Cancer Center Rotterdam the Netherlands
Department of Hematology Hospices Civils de Lyon Lyon Sud Hospital Pierre Bénite France
Department of Hematology Hospital Clínic Barcelona Spain
Department of Hematology Hospital Univ 12 de Octubre Complutense University CNIO Madrid Spain
Department of Hematology Hospital Universitario de La Princesa Madrid Spain
Department of Hematology Hospital Universitario de Salamanca and IBSAL Salamanca Spain
Department of Hematology Leiden University Medical Center Leiden Netherlands
Department of Hematology University Medical Center Utrecht Utrecht Netherlands
Department of Hematology Vall d'Hebron University Hospital Barcelona Spain
Department of Stem cell Transplantation University Hospital Eppendorf Hamburg Germany
Deptartment of Hematology University Hospital Gasthuisberg Leuven Belgium
European Society for Blood and Marrow Transplantation Data Office Leiden Netherlands
Hematology and BMT Unit IRCCS San Raffaele Scientific Institute Milan Italy
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019086
- 003
- CZ-PrNML
- 005
- 20241024111624.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-024-02336-1 $2 doi
- 035 __
- $a (PubMed)39043963
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Spanjaart, Anne Mea $u Department of Hematology, Amsterdam UMC location University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands
- 245 10
- $a Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group / $c AM. Spanjaart, P. Ljungman, G. Tridello, J. Schwartz, N. Martinez-Cibrián, P. Barba, M. Kwon, L. Lopez-Corral, J. Martinez-Lopez, C. Ferra, R. Di Blasi, H. Ghesquieres, P. Mutsaers, F. Calkoen, M. Jak, J. van Doesum, JSP. Vermaat, M. van der Poel, J. Maertens, M. Gambella, E. Metafuni, F. Ciceri, R. Saccardi, E. Nicholson, E. Tholouli, C. Matthew, V. Potter, A. Bloor, C. Besley, C. Roddie, K. Wilson, A. Nagler, A. Campos, SL. Petersen, F. Folber, P. Bader, J. Finke, N. Kroger, N. Knelange, R. de La Camara, MJ. Kersten, S. Mielke
- 520 9_
- $a COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a COVID-19 $x terapie $x imunologie $x mortalita $7 D000086382
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a imunoterapie adoptivní $x metody $x škodlivé účinky $7 D016219
- 650 12
- $a SARS-CoV-2 $x imunologie $7 D000086402
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 12
- $a hematologické nádory $x terapie $x mortalita $x imunologie $7 D019337
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a chimerické antigenní receptory $x imunologie $7 D000076962
- 650 _2
- $a míra přežití $7 D015996
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Ljungman, Per $u Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden
- 700 1_
- $a Tridello, Gloria $u European Society for Blood and Marrow Transplantation (EBMT) Data Office, Department of Medical Statistics & Bioinformatics, Leiden, Netherlands
- 700 1_
- $a Schwartz, Juana $u European Society for Blood and Marrow Transplantation (EBMT) Leiden Study Unit, European Society for Blood and Marrow Transplantation (EBMT) Data Office, Leiden, Netherlands
- 700 1_
- $a Martinez-Cibrián, Nuria $u Department of Hematology, Hospital Clínic, Barcelona, Spain
- 700 1_
- $a Barba, Pere $u Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain $1 https://orcid.org/0000000310385197
- 700 1_
- $a Kwon, Mi $u Department of Hematology, Hospital G. Universitario Gregorio Marañon, Institute of Health Research Gregorio Marañon, Madrid, Spain
- 700 1_
- $a Lopez-Corral, Lucia $u Department of Hematology, Hospital Universitario de Salamanca and IBSAL, Salamanca, Spain $1 https://orcid.org/0000000319085596
- 700 1_
- $a Martinez-Lopez, Joaquin $u Department of Hematology, Hospital Univ. 12 de Octubre, Complutense University, CNIO, Madrid, Spain $1 https://orcid.org/0000000179080063
- 700 1_
- $a Ferra, Christelle $u Clinical Hematology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Barcelona, Spain
- 700 1_
- $a Di Blasi, Roberta $u Department of Hematology, Assistance Publique Hôpitaux de Paris-Hopital Saint-Louis, Paris, France
- 700 1_
- $a Ghesquieres, Hervé $u Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
- 700 1_
- $a Mutsaers, Pim $u Department of Hematology, Erasmus MC Cancer Center, Rotterdam, the Netherlands $1 https://orcid.org/0000000239248578
- 700 1_
- $a Calkoen, Friso $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $1 https://orcid.org/0000000190590929
- 700 1_
- $a Jak, Margot $u Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
- 700 1_
- $a van Doesum, Jaap $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands $1 https://orcid.org/0000000302143219
- 700 1_
- $a Vermaat, Joost S P $u Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
- 700 1_
- $a van der Poel, Marjolein $u Department of Hematology, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands
- 700 1_
- $a Maertens, Johan $u Deptartment of Hematology, University Hospital Gasthuisberg, Leuven, Belgium $1 https://orcid.org/0000000342575980
- 700 1_
- $a Gambella, Massimiliano $u Department of Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 700 1_
- $a Metafuni, Elisabetta $u Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica e Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Ciceri, Fabio $u Hematology and BMT Unit IRCCS San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Saccardi, Riccardo $u Cell Therapy and Transfusion Medicine Unit Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
- 700 1_
- $a Nicholson, Emma $u Department of Haematology, The Royal Marsden Hospital, London, United Kingdom $1 https://orcid.org/0000000264390795
- 700 1_
- $a Tholouli, Eleni $u Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
- 700 1_
- $a Matthew, Collin $u Adult HSCT unit, Northern Centre for Bone Marrow Transplantation, Newcastle Tyne, UK
- 700 1_
- $a Potter, Victoria $u King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, UK
- 700 1_
- $a Bloor, Adrian $u Adult Leukaemia and Bone Marrow Transplant Unit, Christie NHS Foundation Trust Hospital, University of Manchester, Manchester, UK
- 700 1_
- $a Besley, Caroline $u Department of Haematology, University Hospitals Bristol and Weston NHSFT, Bristol, UK
- 700 1_
- $a Roddie, Claire $u Department of Haematology, University College London Hospital, London, UK
- 700 1_
- $a Wilson, Keith $u Blood and Bone Marrow Transplantation Department, University Hospital of Cardiff, Cardiff, UK $1 https://orcid.org/0000000263279366
- 700 1_
- $a Nagler, Arnon $u Chaim Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel
- 700 1_
- $a Campos, Antonio $u Celular Therapy Department, Instituto Portugués de Oncologia do Porto, Francisco Gentil, E.P.E, Porto, Portugal
- 700 1_
- $a Petersen, Soeren Lykke $u Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Folber, Frantisek $u Department of internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/000000017034769X
- 700 1_
- $a Bader, Peter $u Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
- 700 1_
- $a Finke, Jurgen $u Department of Hematology/Oncology/Stem Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany $1 https://orcid.org/0000000217995927
- 700 1_
- $a Kroger, Nicolaus $u Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000151039966
- 700 1_
- $a Knelange, Nina $u European Society for Blood and Marrow Transplantation (EBMT) Leiden Study Unit, European Society for Blood and Marrow Transplantation (EBMT) Data Office, Leiden, Netherlands
- 700 1_
- $a de La Camara, Rafael $u Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain $1 https://orcid.org/0000000281895779
- 700 1_
- $a Kersten, Marie José $u Department of Hematology, Amsterdam UMC location University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands $1 https://orcid.org/0000000289043802
- 700 1_
- $a Mielke, Stephan $u Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Department of Laboratory Medicine, Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden. stephan.mielke@ki.se $u Cellular Therapy and immunobiology working party (CTIWP) of EBMT, . stephan.mielke@ki.se $1 https://orcid.org/0000000301676021
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 38, č. 9 (2024), s. 1985-1991
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39043963 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111618 $b ABA008
- 999 __
- $a ok $b bmc $g 2201731 $s 1231059
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 9 $d 1985-1991 $e 20240723 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20241015
